Zanubrutinib is Well Tolerated and Effective in Acalabrutinib-Intolerant Patients with B-cell Malignancies

被引：0
|
作者：
Shadman, Mazyar [1 ,2 ]
Flinn, Ian W. [3 ]
Levy, Moshe Y. [4 ]
Freeman, Benjamin B. [5 ]
Zhang, Ben [6 ]
Burke, John M. [7 ]
Cultrera, Jennifer L. [8 ]
Yimer, Habte A. [9 ]
Kingsley, Edwin C. [10 ]
Farber, Charles M. [11 ]
D'Olimpio, James [12 ]
Yao, Hui [13 ]
Idoine, Adam [14 ]
An, Qi [13 ]
Sharman, Jeff P. [15 ]
机构：
[1] Fred Hutchinson Canc Res Ctr, Seattle, WA USA
[2] Univ Washington, Seattle, WA USA
[3] Tennessee Oncol, OneOncol, Nashville, TN USA
[4] Texas Oncol Baylor Charles A Sammons Canc Ctr, Dallas, TX USA
[5] Summit Med Grp, Florham Pk, NJ USA
[6] Minnesota Oncol Clin, Burnsville, MN USA
[7] US Oncol Res, Rocky Mt Canc Ctr, Aurora, CO USA
[8] Florida Canc Specialists & Res Inst, Leesburg, FL USA
[9] US Oncol Res, Texas Oncol Tyler, Tyler, TX USA
[10] Comprehens Canc Ctr Nevada, Las Vegas, NV USA
[11] Morristown Med Ctr, Atlantic Hematol Oncol, Morristown, NJ USA
[12] Clin Res Alliance, Westbury, NY USA
[13] BeiGene Shanghai Co Ltd, Shanghai, Peoples R China
[14] BeiGene USA Inc, San Mateo, CA USA
[15] US Oncol Res, Willamette Valley Canc Inst & Res Ctr, Eugene, OR USA
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-198250
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：4632 / 4633
页数：2
相关论文
共 50 条
  • [41] Clinician Perspective on Once-Daily Zanubrutinib Dosing for B-Cell Malignancies at a Single Center
    Narang, Mohit
    Horn, Courtney
    Lee, Edward
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2024, 18
  • [42] Rituximab in Combination with CHOP, an Effective and Well-tolerated Salvage Regimen for Diffuse Large B-Cell Lymphoma
    Yong Guan1 Zhenxia Lu2 Butong Sun2 Lintao Bi2 Pengyu Zhang3 1 Department of Hematology and Oncology
    Chinese Journal of Clinical Oncology, 2007, (04) : 264 - 267
  • [43] A Phase 1 Study With the Novel B-Cell Lymphoma 2 Inhibitor BGB-11417 as Monotherapy or in Combination With Zanubrutinib in Patients With B-Cell Malignancies: Preliminary Data
    Soumerai, Jacob D.
    Opat, Stephen
    Cheah, Chan Y.
    Lasica, Masa
    Verner, Emma
    Browett, Peter J.
    Chan, Henry
    Barca, Eva Gonzalez
    Hilger, James
    Fang, Yiqian
    Simpson, David
    Tam, Constantine S.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S267 - S268
  • [44] Exposure-response analysis of acalabrutinib and its active metabolite, ACP-5862, in patients with B-cell malignancies
    Edlund, Helena
    Buil-Bruna, Nuria
    Vishwanathan, Karthick
    Wei, Helen
    Raman, Rakesh
    de Kock, Mine
    He, Zhongqing
    Liu, Huan
    Baek, Marshall
    Ware, Joseph
    Patel, Priti
    Tomkinson, Helen
    Sharma, Shringi
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 88 (05) : 2284 - 2296
  • [45] DISTURBANCES IN HEMOSTASIS IN PATIENTS WITH B-CELL MALIGNANCIES
    GLASPY, JA
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 1992, 18 (04): : 440 - 448
  • [46] CHRONIC B-CELL MALIGNANCIES IN PATIENTS WITH LYMPHOCYTOSIS
    HUNT, KM
    STEED, A
    MORGAN, MAM
    BYNOE, AG
    PARAPIA, LA
    SCOTT, CS
    LEUKEMIA & LYMPHOMA, 1990, 2 (3-4) : 257 - 258
  • [47] Safety and antitumor activity of acalabrutinib for relapsed/refractory B-cell malignancies: A Japanese phase I study
    Izutsu, Koji
    Ando, Kiyoshi
    Ennishi, Daisuke
    Shibayama, Hirohiko
    Suzumiya, Junji
    Yamamoto, Kazuhito
    Ichikawa, Satoshi
    Kato, Koji
    Kumagai, Kyoya
    Patel, Priti
    Iizumi, Sakura
    Hayashi, Nobuya
    Kawasumi, Hisashi
    Murayama, Kosho
    Nagai, Hirokazu
    CANCER SCIENCE, 2021, 112 (06) : 2405 - 2415
  • [48] All-Oral Low-Dose Chemotherapy TEPIP is Effective and Well-Tolerated in Relapsed/Refractory Patients With Aggressive B-Cell Lymphoma
    Fante, Matthias A.
    Felsenstein, Mona
    Mayer, Stephanie
    Gerken, Michael
    Klinkhammer-Schalke, Monika
    Herr, Wolfgang
    Vogelhuber, Martin
    Reichle, Albrecht
    Heudobler, Daniel
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [49] Second reduced-intensity transplants are effective and well tolerated in older patients with relapsed myeloid malignancies
    Chen, FE
    Ahmad, HN
    Junagade, P
    Lim, Z
    Devereux, S
    Pagliuca, A
    Ho, A
    Mufti, GJ
    BONE MARROW TRANSPLANTATION, 2006, 37 : S192 - S192
  • [50] Population pharmacokinetics of lenalidomide in patients with B-cell malignancies
    Hughes, Jim H.
    Phelps, Mitch A.
    Upton, Richard N.
    Reuter, Stephanie E.
    Gao, Yue
    Byrd, John C.
    Grever, Michael R.
    Hofmeister, Craig C.
    Marcucci, Guido
    Blum, William
    Blum, Kristie A.
    Foster, David J. R.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 85 (05) : 924 - 934
12345